Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases
Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases
复制标题
DOI：
10.1111/j.1478-3231.2007.01559.x
复制
发表时间：
2007-11-01
影响因子：
6.7
通讯作者：
Sata, Michio
中科院分区：
文献类型：
--
作者：
Kawaguchi, Takumi;Taniguchi, Eitaro;Sata, Michio
丙型肝炎病毒（HCV）感染引起胰岛素抵抗。由于胰岛素抵抗增加是肝细胞癌发展和长期生存率降低的危险因素，因此胰岛素抵抗是HCV感染患者的治疗靶点。支链氨基酸（BCAA）不仅是蛋白质的结构成分，而且也被认为是胰岛素信号的调节剂。我们首先描述了两个病例，表明支链氨基酸的管理，改善胰岛素抵抗与HCV相关的肝脏疾病。尽管体重无变化，但血糖浓度和血红蛋白A1c（HbA1c）值降低。此外，支链氨基酸引起空腹胰岛素浓度和胰岛素抵抗的稳态模型评估值下降。因此，支链氨基酸是改善HCV相关肝病患者胰岛素抵抗的潜在治疗剂。
Hepatitis C virus (HCV) infection causes insulin resistance. Because increased insulin resistance is a risk factor for development of hepatocellular carcinoma and reduced long-term survival, insulin resistance is a therapeutic target in patients with HCV infection. Branched-chain amino acids (BCAAs) are not only structural constituents of proteins but they are also considered as regulators of insulin signalling. We first describe two cases suggesting that administration of BCAAs improves insulin resistance associated with HCV-related liver disease. Although there were no changes in body weight, plasma glucose concentration and haemoglobin A1c (HbA1c) value were decreased. Moreover, BCAAs caused a decrease in both fasting insulin concentration and the value of homeostasis model assessment for insulin resistance. Thus, BCAAs are a potential therapeutic agent for improving insulin resistance in patients with HCV-related liver disease.